Immunogenic Properties of the DNA Construct Encoding the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein
The development of preventive vaccines became the first order task in the COVID-19 pandemic caused by SARS-CoV-2. This paper reports the construction of the pVAX-RBD plasmid containing the Receptor-Binding Domain (RBD) of the S protein and a unique signal sequence 176 which promotes target protein secretion into the extracellular space thereby increasing the efficiency of humoral immune response activation. A polyglucine-spermidine conjugate (PGS) was used to deliver pVAX-RBD into the cells. The comparative immunogenicity study of the naked pVAX-RBD and pVAX-RBD enclosed in the PGS envelope showed that the latter was more efficient in inducing an immune response in the immunized mice. In particular, RBD-specific antibody titers were shown in ELISA to be no higher than 1 : 1000 in the animals from the pVAX-RBD group and 1 : 42000, in the pVAX-RBD-PGS group. The pVAX-RBD-PGS construct effectively induced cellular immune response. Using ELISpot, it has been demonstrated that splenocytes obtained from the immunized animals effectively produced INF-y in response to stimulation with the S protein-derived peptide pool. The results suggest that the polyglucine-spermidine conjugate-enveloped pVAX-RBD construct may be considered as a promising DNA vaccine against COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:55 |
|---|---|
| Enthalten in: |
Molekuliarnaia biologiia - 55(2021), 6 vom: 27. Nov., Seite 987-998 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
Borgoyakova, M B [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9007-49-2 |
|---|
| Anmerkungen: |
Date Completed 30.11.2021 Date Revised 30.11.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.31857/S0026898421060045 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333748190 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333748190 | ||
| 003 | DE-627 | ||
| 005 | 20231225222303.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.31857/S0026898421060045 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1112.xml |
| 035 | |a (DE-627)NLM333748190 | ||
| 035 | |a (NLM)34837703 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 1 | |a Borgoyakova, M B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunogenic Properties of the DNA Construct Encoding the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.11.2021 | ||
| 500 | |a Date Revised 30.11.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The development of preventive vaccines became the first order task in the COVID-19 pandemic caused by SARS-CoV-2. This paper reports the construction of the pVAX-RBD plasmid containing the Receptor-Binding Domain (RBD) of the S protein and a unique signal sequence 176 which promotes target protein secretion into the extracellular space thereby increasing the efficiency of humoral immune response activation. A polyglucine-spermidine conjugate (PGS) was used to deliver pVAX-RBD into the cells. The comparative immunogenicity study of the naked pVAX-RBD and pVAX-RBD enclosed in the PGS envelope showed that the latter was more efficient in inducing an immune response in the immunized mice. In particular, RBD-specific antibody titers were shown in ELISA to be no higher than 1 : 1000 in the animals from the pVAX-RBD group and 1 : 42000, in the pVAX-RBD-PGS group. The pVAX-RBD-PGS construct effectively induced cellular immune response. Using ELISpot, it has been demonstrated that splenocytes obtained from the immunized animals effectively produced INF-y in response to stimulation with the S protein-derived peptide pool. The results suggest that the polyglucine-spermidine conjugate-enveloped pVAX-RBD construct may be considered as a promising DNA vaccine against COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a DNA vaccine | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a immune response | |
| 650 | 4 | |a mouse model | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 650 | 7 | |a DNA |2 NLM | |
| 650 | 7 | |a 9007-49-2 |2 NLM | |
| 700 | 1 | |a Karpenko, L I |e verfasserin |4 aut | |
| 700 | 1 | |a Rudometov, A P |e verfasserin |4 aut | |
| 700 | 1 | |a Shanshin, D V |e verfasserin |4 aut | |
| 700 | 1 | |a Isaeva, A A |e verfasserin |4 aut | |
| 700 | 1 | |a Nesmeyanova, V S |e verfasserin |4 aut | |
| 700 | 1 | |a Volkova, N V |e verfasserin |4 aut | |
| 700 | 1 | |a Belenkaya, S V |e verfasserin |4 aut | |
| 700 | 1 | |a Murashkin, D E |e verfasserin |4 aut | |
| 700 | 1 | |a Shcherbakov, D N |e verfasserin |4 aut | |
| 700 | 1 | |a Volosnikova, E A |e verfasserin |4 aut | |
| 700 | 1 | |a Starostina, E V |e verfasserin |4 aut | |
| 700 | 1 | |a Orlova, L A |e verfasserin |4 aut | |
| 700 | 1 | |a Danilchenko, N V |e verfasserin |4 aut | |
| 700 | 1 | |a Zaikovskaya, A V |e verfasserin |4 aut | |
| 700 | 1 | |a Pyankov, O V |e verfasserin |4 aut | |
| 700 | 1 | |a Ilyichev, A A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molekuliarnaia biologiia |d 1975 |g 55(2021), 6 vom: 27. Nov., Seite 987-998 |w (DE-627)NLM000033979 |x 0026-8984 |7 nnns |
| 773 | 1 | 8 | |g volume:55 |g year:2021 |g number:6 |g day:27 |g month:11 |g pages:987-998 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.31857/S0026898421060045 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 55 |j 2021 |e 6 |b 27 |c 11 |h 987-998 | ||